Camurus shares rise after Q2 revenue, operating profit beat

Camurus AB

15/07/2026 08:12

    ** Shares in Camurus  CAMX.ST  rise 10% after the Swedish
biotech reported Q2 results above estimates
    ** Its revenue reached SEK 702 million ($72.8 million),
above IBES estimates of SEK 632.8 million
    ** Jefferies says revenue beat was driven by sales of
injectable opioid-use disorder drugs Brixadi and Buvidal, with
$5 million milestone from partnership with Eli Lilly  LLY.N 
already "in the numbers"
    ** Operating profit for the quarter was SEK 293 million,
beating IBES estimate of SEK 232 million
    ** Higher revenues, with in-line gross margin and operating
expenses drove up the operating profit beat, Jefferies says
    ** Jefferies estimates Camurus will resubmit an application
to the FDA for its Oclaiz hormone disorder drug by Q4 this year
    ** Shares were up 10% at 07:01 GMT, on track for their best
day since November 2025 if gains hold

($1 = 9.6490 Swedish crowns)

 (Reporting by Vera Dvorakova)
 ((vera.dvorakova@thomsonreuters.com))